Processing Safety Signals
Our Experts Carry Out Benefit-Risk Analysis
Drugs safety monitoring activities include the collection and organising of drug safety data. It is imperative that any new safety findings observed in patterns be accurately and timely identified. The appropriate evaluation and timely identification of possible signals is an important Pharmacovigilance activity which will in turn protect your patients as well as your company against any lawsuit and action taken by regulators.
Signals become complex when they specify potential new risks in relation to a particular medicinal product, or when the potential for the expected risks change. The data which informs the signal detection process comes from various sources such as Pharmacovigilance Literature Screening, other types of non-clinical, non-interventional studies and other forms of active assessment including risk-benefit monitoring. Almond Pharma Pharmacovigilance services consultants make sure your Safety Signals Management activities are systematically comprehensive and compliantly processed.
Our consultants include industry experts who have long been at the forefront of this activity. We are adept at identifying and evaluating signals, and we take pride in our common-sense approach to the matter simplifying the process and ultimately reducing your costs. Our experts carry out benefit-risk analysis and can help you communicate effectively the message about new safety concerns. Our experts can communicate this message to both individuals within your company and regulatory authorities.
© 2020 ASAAL ltd
Registered in the UK, Company number 06830591